847 related articles for article (PubMed ID: 31673240)
1. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
2. KRAS Mutation-Responsive miR-139-5p inhibits Colorectal Cancer Progression and is repressed by Wnt Signaling.
Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
[No Abstract] [Full Text] [Related]
3. MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers.
Choi YW; Song YS; Lee H; Yi K; Kim YB; Suh KW; Lee D
Medicine (Baltimore); 2016 Apr; 95(15):e3321. PubMed ID: 27082577
[TBL] [Abstract][Full Text] [Related]
4. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
Weng WH; Leung WH; Pang YJ; Hsu HH
Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
[TBL] [Abstract][Full Text] [Related]
5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
6. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.
Igarashi H; Kurihara H; Mitsuhashi K; Ito M; Okuda H; Kanno S; Naito T; Yoshii S; Takahashi H; Kusumi T; Hasegawa T; Sukawa Y; Adachi Y; Okita K; Hirata K; Imamura Y; Baba Y; Imai K; Suzuki H; Yamamoto H; Nosho K; Shinomura Y
Ann Surg Oncol; 2015 Aug; 22(8):2640-8. PubMed ID: 25472647
[TBL] [Abstract][Full Text] [Related]
7. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs?
Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A
J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
Xing Y; Jing H; Zhang Y; Suo J; Qian M
Int J Biochem Cell Biol; 2020 Jan; 118():105643. PubMed ID: 31704502
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA Expression in
Lundberg IV; Wikberg ML; Ljuslinder I; Li X; Myte R; Zingmark C; Löfgren-Burström A; Edin S; Palmqvist R
Anticancer Res; 2018 Feb; 38(2):677-683. PubMed ID: 29374690
[TBL] [Abstract][Full Text] [Related]
10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
11. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
13. miRNAs-Based Molecular Signature for
Milanesi E; Dobre M; Bucuroiu AI; Herlea V; Manuc TE; Salvi A; De Petro G; Manuc M; Becheanu G
J Immunol Res; 2020; 2020():4927120. PubMed ID: 32676506
[TBL] [Abstract][Full Text] [Related]
14. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
Kiss I; Mlcochova J; Bortlicek Z; Poprach A; Drabek J; Vychytilova-Faltejskova P; Svoboda M; Buchler T; Batko S; Ryska A; Hajduch M; Slaby O
Anticancer Res; 2016 Sep; 36(9):4955-9. PubMed ID: 27630355
[TBL] [Abstract][Full Text] [Related]
17. Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC).
Zhang T; Cai X; Li Q; Xue P; Chen Z; Dong X; Xue Y
Oncotarget; 2016 Jul; 7(27):42225-42240. PubMed ID: 27302926
[TBL] [Abstract][Full Text] [Related]
18. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment.
Ragusa M; Majorana A; Statello L; Maugeri M; Salito L; Barbagallo D; Guglielmino MR; Duro LR; Angelica R; Caltabiano R; Biondi A; Di Vita M; Privitera G; Scalia M; Cappellani A; Vasquez E; Lanzafame S; Basile F; Di Pietro C; Purrello M
Mol Cancer Ther; 2010 Dec; 9(12):3396-409. PubMed ID: 20881268
[TBL] [Abstract][Full Text] [Related]
19. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
20. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
